GENOCEA TO PRESENT AT THE STIFEL NICOLAUS 2013 HEALTHCARE CONFERENCE
CAMBRIDGE, Mass., Sept., 5, 2013—Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T-cell vaccines to prevent and treat infectious diseases, announced today that its chief executive officer, Chip Clark, will present a company overview at the Stifel Nicolaus 2013 Healthcare Conference. The presentation is scheduled for Wednesday, Sept. 11, 2013 at 8:35 a.m. EDT at the Four Seasons Hotel in Boston, Mass.
About Genocea
Genocea is harnessing the power of T-cell immunity to develop the next generation of vaccines. T cells are increasingly recognized as a critical element of a protective immune response to a wide range of infectious disease pathogens but are difficult to target using traditional vaccine discovery methods. Genocea is uniquely able to identify protective T-cell antigens in humans exposed to a pathogen using ATLAS™, its proprietary technology platform that mimics the human immune response in the laboratory, potentially improving the effectiveness of vaccine candidates and drastically reducing the time needed to create them.
Genocea’s pipeline of novel T cell vaccines includes GEN-003 for HSV-2 therapy, GEN-004, a protein vaccine directed at pneumococcus that is expected to enter the clinic in the fourth quarter of 2013, and earlier-stage programs in chlamydia, HSV-2 prophylaxis and malaria. Positive data from an interim analysis of Genocea’s Phase 1/2a clinical study of GEN-003 will be presented on Sept. 12 at ICAAC 2013.
For more information, please visit the company’s website at www.genocea.com.
